3.52
+5.07%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Senzime AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker SEZI.ST. It has been listed since 18 June 2008. In the fiscal year to 31 December 2025, it reported revenue of SEK 104.0m and a net loss of SEK 137.4m. At that date it held total assets of SEK 369.8m and shareholders' equity of SEK 304.5m.
Senzime AB engages in the development of enzyme-based biosensor technology for medical and biochemical processes and industries. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2008-06-18. The firm focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 18 Jun 2008
- Employees
- 12
- Website
- senzime.com ↗
Leadership
Pay as last reported
- Mr. Per Wold-OlsenIndependent Chairman of the BoardSEK 487,000
- Mr. G. W. HamiltonPresident - Senzime Inc.
- Mr. Philip SibergChief Executive Officer, since 2015SEK 4.7m
- Mr. Adam DahlbergDeputy Chairman of the Board, since 2000SEK 300,000
- Mr. Slavoljub GrujicicChief Financial Officer
- Ms. Johanna TulkkiChief Operating Officer, Executive Vice President
- Mr. Anders JacobsonChief Scientific Officer
- Mr. Michael NobleVice President of Global Marketing
- Dr. Sorin BrullExecutive Director, Chief Medical Officer, since 2016SEK 1.3m
- Ms. Johanna FarisHead of Quality Assurance and Regulatory Affairs
- Mr. Lars AxelsonDirectorSEK 210,000
- Mr. Goeran BrorssonIndependent DirectorSEK 210,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 35
- Environment
- 24
- Social
- 54
- Governance
- 27
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Senzime AB (publ) prides itself on delivering high-quality products and innovative technology. The company's commitment to research and development enables them to offer advanced medical devices and solutions that meet the needs of healthcare professionals and patients.
- Senzime AB (publ) has successfully established a strong market presence in the medical device industry. The company's brand reputation, customer trust, and global distribution network contribute to its competitive advantage. This solid market position helps attract new customers and retain existing ones.
Weaknesses
- Senzime AB (publ) relies heavily on specific market segments for its revenue generation. Any downturn or disruption in these markets could potentially impact the company's financial performance. Actively diversifying into new healthcare sectors could help mitigate this weakness.
- As a relatively small company, Senzime AB (publ) may face resource constraints in terms of capital, marketing, and distribution capabilities. This could limit the company's ability to compete with larger players in the industry. However, the company's agility and focus on niche markets can also be seen as an advantage.
Opportunities
- The global medical device market is experiencing significant growth due to increasing healthcare expenditure, aging population, and advancements in technology. Senzime AB (publ) is well-positioned to capitalize on this opportunity by expanding its product portfolio and entering new markets.
- Forming strategic partnerships and collaborations with leading technology companies or healthcare institutions can provide Senzime AB (publ) with access to new technologies, expertise, and resources. This can facilitate product development and enhance the company's competitive advantage.
Threats
- The medical device industry is highly competitive, with numerous established players and new entrants. Senzime AB (publ) faces the risk of competitors offering similar products, effectively capturing market share, or engaging in aggressive pricing strategies. Continuous innovation and differentiation are crucial to mitigate this threat.
- Operating in the medical device sector requires strict adherence to regulatory standards and compliance with various healthcare regulations. Changes in regulations or failure to comply might lead to delayed product approvals, increased costs, or reputational damage. Senzime AB (publ) must stay updated and ensure compliance to minimize such risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.